Purpose [18F]-2-Fluoro-2-deoxy-D-glucose PET/CT (FDG PET/CT) is a sensitive and quantitative technic for detecting inflammatory process. Glucose uptake is correlated with an increased anaerobic glycolysis seen in activated inflammatory cells such as monocytes, lymphocytes, and granulocytes. The aim of the study was to assess the inflammatory status at the presumed peak of the inflammatory phase in non-critically ill patients requiring admission for COVID-19. Methods Patients admitted with COVID-19 were prospectively enrolled. FDG PET/CT was performed from day 6 to day 14 of the onset of symptoms. Depending on FDG PET/CT findings, patients' profiles were classified as "inflammatory" or "low inflammatory." FDG PET/CT data were compared with chest CT evolution and short-term clinical outcome. All inflammatory sites were reported to screen potential extra-pulmonary tropism. Results Thirteen patients were included. Maximum standardized uptake values ranged from 4.7 to 16.3 in lungs. All patients demonstrated increased mediastinal lymph nodes glucose uptake. Three patients (23%) presented mild nasopharyngeal, two patients (15%) bone marrow, and five patients (38%) splenic mild increase in glucose uptake. No patient had significant digestive focal or segmental glucose uptake. There was no significant physiological myocardial glucose uptake in all patients except one. There was no correlation between PET lung inflammatory status and chest CT evolution or short-term clinical outcome. Conclusion Inflammatory process at the presumed peak of the inflammatory phase in COVID-19 patients is obvious in FDG PET/CT scans. Glucose uptake is heterogeneous and typically focused on lungs. Trial registration NCT04441489. Registered 22 June 2020 (retrospectively registered).

No abstract

Background To investigate whether routine biomarkers and blood leucocytes count could assist diagnosis of COVID-19-associated pneumonia in adult patients visiting the emergency department (ED). Methods This monocentre retrospective study enrolled 254 patients with nasopharyngeal RT-PCR for SARS-COV-2, routine biomarkers (D-dimers, fibrinogen, C-reactive protein, procalcitonin, NTpro-BNP, cTnT-hs) and blood cell counts. Sensitivity and specificity were evaluated. An adjudication committee classified diagnostic probability as certain, probable, unlikely, and excluded, based on all available data, then distributed in 2 categories: high (certain and probable) and low probability (unlikely and excluded). Results Between 25 th of February and 15 th of April, 2020, 254 of 388 patients could be analyzed. The adjudication committee classified 46 patients as definite, 18 as probable, 64 as unlikely, and 126 as excluded, corresponding to 64 high and 190 low probability. High and low probability patients differed for fibrinogen (P<0.0005) and white blood cell counts, notably leucocytes (P=0.0015), neutrophilic (P=0.0036), lymphocytes (P=0.0057), eosinophilic (P=0.027), and basophilic (P<0.001) counts. In a multivariate analysis, basophilic count < 25/µL (OR 3.048 [95%CI; 1.34-6.919]), neutrophilic count < 4000 /µL (OR 5.525 [95%CI; 2.20-13.855], and fibrinogen > 3g/L (OR 6355 [95%CI; 2.01-20.079] were independently associated with the diagnosis. Negative predictive values were 0.98 and 0.93 combining fibrinogen ( < 3g/L) and eosinophilic count ( < 80/µL), and fibrinogen and basophilic count ( < 25/µL), respectively. Conclusion Changes in fibrinogen and white blood cells, notably basophilic count, showed interesting performance for the diagnosis COVID-19 associated pneumonia. Combining fibrinogen with either eosinophilic or basophilic count was helpful to exclude the diagnosis.

No abstract

No abstract